Skip to main content

Table 1 Association between MICAL-L2 expression and clinicopathologic features in the validation cohort

From: High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma

Characteristic

levels

Low expression of MICALL2

High expression of MICALL2

p

n

 

227

227

 

T stage, n (%)

T1

4 (0.9%)

7 (1.5%)

0.389

T2

43 (9.5%)

34 (7.5%)

 

T3

155 (34.2%)

154 (34%)

 

T4

24 (5.3%)

32 (7.1%)

 

N stage, n (%)

N0

140 (30.8%)

127 (28%)

0.301

N1

52 (11.5%)

53 (11.7%)

 

N2

35 (7.7%)

47 (10.4%)

 

M stage, n (%)

M0

164 (41.3%)

169 (42.6%)

0.666

M1

34 (8.6%)

30 (7.6%)

 

Pathologic stage, n (%)

Stage I

41 (9.3%)

34 (7.7%)

0.185

Stage II

94 (21.2%)

82 (18.5%)

 

Stage III

54 (12.2%)

74 (16.7%)

 

Stage IV

34 (7.7%)

30 (6.8%)

 

Primary therapy outcome, n (%)

PD

10 (4.3%)

15 (6.4%)

0.214

SD

1 (0.4%)

3 (1.3%)

 

PR

4 (1.7%)

8 (3.4%)

 

CR

105 (44.7%)

89 (37.9%)

 

Gender, n (%)

Female

104 (22.9%)

110 (24.2%)

0.638

Male

123 (27.1%)

117 (25.8%)

 

Age, n (%)

<=65

100 (22%)

88 (19.4%)

0.295

> 65

127 (28%)

139 (30.6%)

 

Lymphatic invasion, n (%)

NO

137 (33.3%)

111 (27%)

0.048

YES

73 (17.8%)

90 (21.9%)

Â